Real-World Strategies and Case Studies
Peptide therapeutics are opening new opportunities to address challenging biological targets that are difficult to reach with traditional small molecules and biologics. Among these, cyclic and conjugated peptides have emerged as promising modalities. Cyclization can enhance peptide stability, potency, and selectivity, while conjugation can improve targeting, tissue distribution, half-life, and overall therapeutic performance. Despite their potential, the development of these molecules often involves significant challenges in synthesis, scale-up, manufacturability, and DMPK optimization.
In this webinar, Dr. Arijit Banerjee will discuss how Aragen’s PeptARx platform enables the integrated discovery, development, and scalable manufacture of complex peptides and peptide conjugates. By combining design, synthesis, screening, DMPK evaluation, and development expertise within a single platform, PeptARx helps accelerate timelines while reducing development risk.
Through real-world case studies, attendees will learn how challenging peptide conjugates were successfully synthesized and advanced, and how key synthesis, developability, and DMPK hurdles associated with cyclic peptides were overcome to support candidate progression.
Key takeaways:
PeptARx supports virtually every class of therapeutic and research-grade peptide, including:
